Novo Nordisk Transfers Parkinson's Therapy to AI Startup

Novo Nordisk A/S has entered into an agreement to transfer an experimental therapy for Parkinson's disease to an artificial intelligence startup backed by Mark Zuckerberg. This strategic move is intended to accelerate the development of the promising treatment. By leveraging the AI startup's advanced technological capabilities and potentially faster development processes, Novo Nordisk aims to expedite the path from research to clinical application for patients suffering from Parkinson's disease.